Herpes simplex virus-2 (HSV-2) suppression with acyclovir or valacyclovir reduces HIV-1 viral RNA levels; one hypothesis is that HSV-2 suppression reduces immune activation. We measured T cell immune activation markers among women participating in a randomized placebo-controlled trial of valacyclovir to reduce HIV-1 RNA levels among pregnant women. Although valacyclovir was associated with lower HIV-1 RNA levels, the distribution of both CD4+ and CD8+ CD38+HLA-DR+ T cells was not different among women taking valacyclovir when compared to women taking placebo. Further study is needed to understand the mechanism of HIV-1 RNA reduction following herpes suppression among those coinfected with HIV-1 and HSV-2.
Get full access to this article
View all access options for this article.
References
1.
ShethPM, SunderjiS, ShinLYet al.Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis, 2008; 197,10:1394–1401.
2.
OuedraogoA, NagotN, VergneLet al.Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: A randomized controlled trial. AIDS, 2006; 20,18:2305–2313.
3.
NagotN, OuedraogoA, FoulongneVet al.Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med, 2007; 356,8:790–799.
4.
LingappaJR, BaetenJM, WaldAet al.Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: A randomised placebo-controlled trial. Lancet, 2010; 375,9717:824–833.
5.
LawnSD, ButeraST, FolksTM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev, 2001; 14,4:753–777.
6.
ClericiM, ButtoS, LukwiyaMet al.Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS, 2000; 14,14:2083–2092.
7.
HuntPW, CaoHL, MuzooraCet al.Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS, 2011; 25,17:2123–2131.
8.
DrakeAL, RoxbyAC, Ongecha-OwuorFet al.Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: A randomized trial. J Infect Dis, 2012; 205,3:366–375.
9.
RoxbyAC, DrakeAL, Ongecha-OwuorFet al.Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2. PLoS ONE, 2012; 7,6:e38622.
10.
ModjarradK, VermundSH. Effect of treating co-infections on HIV-1 viral load: A systematic review. Lancet Infect Dis, 2010; 10,7:455–463.
11.
BarnabasRV, WebbEL, WeissHA, WasserheitJN. The role of coinfections in HIV epidemic trajectory and positive prevention: A systematic review and meta-analysis. AIDS, 2011; 25,13:1559–1573.
12.
LiscoA, VanpouilleC, TchesnokovEPet al.Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe, 2008; 4,3:260–270.
13.
BaetenJM, LingappaJ, BeckIet al.Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. J Infect Dis, 2010; 203,1:117–121.
14.
MoleL, RipichS, MargolisD, HolodniyM. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis, 1997; 176,3:766–770.
15.
ZhuJ, HladikF, WoodwardAet al.Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med, 2009; 15,8:886–892.
16.
SchifferJT, WaldA, SelkeS, CoreyL, MagaretA. The kinetics of mucosal herpes simplex virus-2 infection in humans: Evidence for rapid viral-host interactions. J Infect Dis, 2011; 204,4:554–561.
17.
SchifferJT, MagaretA, SelkeS, CoreyL, WaldA. Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. J Antimicrob Chemother, 2011; 66,11:2593–2600.
18.
CelumC, WaldA, LingappaJRet al.Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med, 2010; 362,5:427–439.
19.
Watson-JonesD, WeissHA, RusizokaMet al.Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med, 2008; 358,15:1560–1571.
20.
HuntPW, MartinJN, SinclairEet al.Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis, 2011; 203,10:1474–1483.
21.
SylwesterAW, MitchellBL, EdgarJBet al.Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med, 2005; 202,5:673–685.
22.
VanpouilleC, LiscoA, DerudasMet al.A new class of dual-targeted antivirals: Monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. J Infect Dis, 2010; 201,4:635–643.
